This is a phase 1 clinical trial studying whether or not oxaloacetate has a positive effect
on patients with Myasthenia Gravis. Patients will be assigned to one of three cohorts which
will determine the dose of oxaloacetate they will be given. Subjects will take the study drug
for 4 weeks and be on placebo for 4 weeks.